Expression of CCL18 and interleukin-6 in the plasma of breast cancer patients as compared with benign tumor patients and healthy controls

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 4, 2011, Pages 1261-1267

  Nariţa, Diana ^a   Seclaman, E ^a   Ursoniu, S ^a   Ilina, R ^a   Cireap, Natalia ^a   Anghel, A ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Breast cancer; CCL18; Cytokines; IL 6; Inflammation

Indexed keywords

BETA CHEMOKINE; CCL18 PROTEIN, HUMAN; ESTROGEN RECEPTOR; IL6 PROTEIN, HUMAN; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; FEMALE; HEALTH; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMOKINES, CC; FEMALE; HEALTH; HUMANS; INTERLEUKIN-6; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTORS, ESTROGEN;

EID: 84855463939     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Héry C, Heanue M, Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database, BMJ, 2010, 341:c3620.
2. Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Böhm-Vélez M, Pisano ED, Jong RA, Evans WP, Morton MJ, Mahoney MC, Larsen LH, Barr RG, Farria DM, Marques HS, Boparai K; ACRIN 6666 Investigators, Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer, JAMA, 2008, 299(18):2151-2163.
3. Nothacker M, Duda V, Hahn M, Warm M, Degenhardt F, Madjar H, Weinbrenner S, Albert US, Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review, BMC Cancer, 2009, 9:335.
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology, American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 2007, 25(33):5287-5312.
5. Mantovani A, Allavena P, Sica A, Balkwill F, Cancer-related inflammation, Nature, 2008, 454(7203):436-444.
6. Coussens LM, Werb Z, Inflammation and cancer, Nature, 2002, 420(6917):860-867.
7. [Fidler IJ, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited, Nat Rev Cancer, 2003, 3(6):453-458.
8. [Ben-Baruch A, Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators, Semin Cancer Biol, 2006, 16(1):38-52.
9. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y, Cytokines in cancer immunity and immunotherapy, Immunol Rev, 2004, 202:275-293.
10. Kim R, Emi M, Tanabe K, Arihiro K, Tumor-driven evolution of immunosuppressive networks during malignant progression, Cancer Res, 2006, 66(11):5527-5536.
11. Lin WW, Karin M, A cytokine-mediated link between innate immunity, inflammation, and cancer, J Clin Invest, 2007, 117(5):1175-1183.
12. Balkwill F, Mantovani A, Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255):539-545.
13. Kishimoto T, Akira S, Narazaki M, Taga T, Interleukin-6 family of cytokines and gp130, Blood, 1995, 86(4):1243-1254.
14. [Kishimoto T, Interleukin-6: from basic science to medicine - 40 years in immunology, Annu Rev Immunol, 2005, 23:1-21.
15. Ishihara K, Hirano T, IL-6 in autoimmune disease and chronic inflammatory proliferative disease, Cytokine Growth Factor Rev, 2002, 13(4-5):357-368.
16. Hodge DR, Hurt EM, Farrar WL, The role of IL-6 and STAT3 in inflammation and cancer, Eur J Cancer, 2005, 41(16):2502-2512.
17. Purohit A, Newman SP, Reed MJ, The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer, Breast Cancer Res, 2002, 4(2):65-69.
18. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincón M, Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells, Cancer Res, 2001, 61(24):8851-8858.
19. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafè M, IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland, J Clin Invest, 2007, 117(12):3988-4002.
20. Knüpfer H, Preiss R, Significance of interleukin-6 (IL-6) in breast cancer (review), Breast Cancer Res Treat, 2007, 102(2):129-135.
21. Takkouche B, Regueira-Méndez C, Etminan M, Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis, J Natl Cancer Inst, 2008, 100(20):1439-1447.
22. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Sandri MT, Mariette F, Lien EA, Decensi A, Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women, J Thromb Haemost, 2003, 1(10):2149-2152.
23. Kodelja V, Müller C, Politz O, Hakij N, Orfanos CE, Goerdt S, Alternative macrophage activation-associated CCchemokine- 1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern, J Immunol, 1998, 160(3):1411-1418.
24. Martinez FO, Helming L, Gordon S, Alternative activation of macrophages: an immunologic functional perspective, Annu Rev Immunol, 2009, 27:451-483.
25. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J, Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activationregulated chemokine in ovarian carcinoma, J Biol Chem, 2002, 277(27):24584-24593.
26. Chang CY, Lee YH, Leu SJ, Wang CY, Wei CP, Hung KS, Pai MH, Tsai MD, Wu CH, CC-chemokine ligand 18/ pulmonary activation-regulated chemokine expression in the CNS with special reference to traumatic brain injuries and neoplastic disorders, Neuroscience, 2010, 165(4):1233-1243.
27. Leung SY, Yuen ST, Chu KM, Mathy JA, Li R, Chan AS, Law S, Wong J, Chen X, So S, Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer, Gastroenterology, 2004, 127(2):457-469.
28. Zohny SF, Fayed ST, Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer, Med Oncol, 2010, 27(4):1246-1253.
29. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P, Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages, Int J Cancer, 2009, 125(2):367-373.
30. Hanahan D, Weinberg RA, The hallmarks of cancer, Cell, 2000, 100(1):57-70.
31. Luster AD, Alon R, von Andrian UH, Immune cell migration in inflammation: present and future therapeutic targets, Nat Immunol, 2005, 6(12):1182-1190.
32. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A, Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, 2002, 23(11):549-555.
33. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM, Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients, J Clin Oncol, 2009, 27(21):3437-3444.
34. de Visser KE, Eichten A, Coussens LM, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer, 2006, 6(1):24-37.
35. [Hadden JW, Immunodeficiency and cancer: prospects for correction, Int Immunopharmacol, 2003, 3(8):1061-1071.
36. DeNardo DG, Coussens LM, Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression, Breast Cancer Res, 2007, 9(4):212.
37. O'Hanlon DM, Lynch J, Cormican M, Given HF, The acute phase response in breast carcinoma, Anticancer Res, 2002, 22(2B):1289-1293.
38. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY, Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients, Br J Cancer, 2003, 88(11):1721-1726.
39. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY, Circulating interleukin-6 predicts survival in patients with metastatic breast cancer, Int J Cancer, 2003, 103(5):642-646.
40. Rook GA, Hernandez-Pando R, Lightman SL, Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance, Immunol Today, 1994, 15(7):301-303.
41. Simard J, Gingras S, Crucial role of cytokines in sex steroid formation in normal and tumoral tissues, Mol Cell Endocrinol, 2001, 171(1-2):25-40.
42. Chen J, Yao Y, Gong C, Yu F, Su S, Chen J, Liu B, Deng H, Wang F, Lin L, Yao H, Su F, Anderson KS, Liu Q, Ewen ME, Yao X, Song E, CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3, Cancer Cell, 2011, 19(4):541-555.